Abstract
Get full access to this article
View all access options for this article.
References
1.
Cibas
ES
,
Ali
SZ
. 2009 . The Bethesda system for reporting thyroid cytopathology . Thyroid , 19 :1159 –1165 .
2.
Ho
AS
,
Sarti
EE
,
Jain
KS
,
Wang
H
,
Nixon
IJ
,
Shaha
AR
,
Shah
JP
,
Kraus
DH
,
Ghossein
R
,
Fish
SA
,
Wong
RJ
,
Lin
O
,
Morris
LG
. 2014 . Malignancy rate in thyroid nodules classified as Bethesda Category III (AUS/FLUS) . Thyroid , 2014 Mar 10 [Epub ahead of print]; DOI:10.1089/thy.2013.0317 .
3.
Nikiforov
YE
,
Ohori
NP
,
Hodak
SP
,
Carty
SE
,
LeBeau
SO
,
Ferris
RL
,
Yip
L
,
Seethala
RR
,
Tublin
ME
,
Stang
MT
,
Coyne
C
,
Johnson
JT
,
Stewart
AF
,
Nikiforova
MN
. 2011 . Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples . J Clin Endocrinol Metab , 96 :3390 –3397 .
4.
Alexander
EK
,
Kennedy
GC
,
Baloch
ZW
,
Cibas
ES
,
Chudova
D
,
Diggans
J
,
Friedman
L
,
Kloos
RT
,
LiVolsi
VA
,
Mandel
SJ
,
Raab
SS
,
Rosai
J
,
Steward
DL
,
Walsh
S
,
Wilde
JI
,
Zieger
MA
,
Lanman
RB
,
Haugen
BR
. 2012 . Preoperative diagnosis of benign thyroid nodules with indeterminate cytology . N Engl J Med , 367 :705 –715 .
5.
McIver
B
. 2013 . Evaluation of the thyroid nodule . Oral Oncol , 49 :645 –653 .